Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Inclusion Criteria: * Have been diagnosed with: * CLL or SLL and have received treatment with the following five classes of therapy: Chemotherapy, anti-cluster of differentiation (anti-cd) 20 antibody, covalent Bruton's tyrosine kinase (BTK) inhibitor, B-cell lymphoma-2 (BCL-2) inhibitor, and phosphatidylinositol 3-kinase (PI3K) inhibitor * MCL that has been previously treated with a covalent BTK inhibitor * Richter's Transformation (RT) with previous Richter's directed-therapy * Waldenstrom macroglobulinemia (WM), previously treated with chemotherapy, anti-CD20 antibody and a covalent BTK inhibitor * Are not eligible for an ongoing pirtobrutinib clinical trial Exclusion Criteria: * Inadequate organ function * Significant cardiovascular disease * History of allogenic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified Tcell (CAR-T) therapy within 60 days * Tested positive for human immunodeficiency syndrome (HIV) or known active hepatitis B or C virus or cytomegalovirus (CMV) infection * Active, uncontrolled autoimmune cytopenia * Clinically significant active malabsorption syndrome * Participants requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist